October 1, 2008
ImClone Commences Enrollment for Phase II Ovarian Cancer Trial
ImClone Systems has announced that the first patient has been treated in its disease-directed Phase II clinical trial of IMC-1121B in patients with advanced ovarian cancer.
This multicenter, open-label Phase II single-arm study is enrolling women with persistent or recurrent advanced ovarian, fallopian tube, and primary peritoneal epithelial cancers following at least one platinum-containing chemotherapy regimen.
IMC-1121B is ImClone's proprietary fully human, IgG1 anti-vascular growth factor receptor-2 monoclonal antibody.
Eric Rowinsky, chief medical officer and executive vice president of ImClone, said: "We are very excited about this proof-of-concept trial, which can serve as a building block for the development of combination studies with IMC-1121B and registration-directed activity in various ovarian cancer settings."